Press releases
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
- Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
- Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
More ▼
Key statistics
As of last trade Blueprint Medicines Corp (0HOJ:LSE) traded at 108.10, -2.23% below its 52-week high of 110.56, set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 108.10 |
Average volume | 294.89 |
---|---|
Shares outstanding | 62.62m |
Free float | 62.08m |
P/E (TTM) | -- |
Market cap | 6.80bn USD |
EPS (TTM) | -4.82 USD |
Data delayed at least 20 minutes, as of May 07 2024 18:52 BST.
More ▼